证券代码： 603811 证券简称： 诚意药业 公告编号：2024-029 浙江诚意药业股份有限公司 关于左卡尼汀注射液获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 一、 概况 浙江诚意药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管理 局（以下简称"国家药监局"）核准签发的左卡尼汀注射液《药品注册证书》，现将 具体情况公告如下： 1、药品名称： 左卡尼汀注射液 5ml：2g； 4、证书编号：2024S02090、2024S02091 12、生产企业地址：浙江省温州市洞头区化工路 118 号 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合 药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及生 产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求方可生产销售。 1 2、剂型：注射剂 3、规格：5ml：1g； 5、药品注册标准编号：YBH19082024 6、申请事项：药品注册(境内生产) 7、注册分类：化学药品 4 类 8、药品有效期： ...

Financial Performance - The company's operating revenue for the first half of 2024 was RMB 355,789,053.38, representing a 10.89% increase compared to RMB 320,859,909.37 in the same period last year[13]. - The net profit attributable to shareholders of the listed company decreased by 15.60% to RMB 76,465,500.27 from RMB 90,599,041.78 year-on-year[13]. - The net cash flow from operating activities fell by 38.45% to RMB 66,091,401.63, down from RMB 107,386,521.93 in the previous year[13]. - The total assets of the company decreased by 5.06% to RMB 1,797,029,727.63 compared to RMB 1,892,765,912.73 at the end of the previous year[13]. - The basic earnings per share for the first half of 2024 was RMB 0.23, a decrease of 17.86% from RMB 0.28 in the same period last year[14]. - The weighted average return on net assets decreased by 1.79 percentage points to 6.27% from 8.06% year-on-year[14]. - The increase in operating revenue was primarily due to sales growth in joint and vitamin products[15]. - The decrease in net profit was mainly attributed to reduced performance from associated companies and increased losses from the subsidiary Jiangsu Chengyi[15]. - The company achieved operating revenue of 355.79 million RMB, representing a year-on-year growth of 10.89%[20]. - The net profit attributable to shareholders was 76.47 million RMB, a decrease of 15.60% compared to the same period last year[20]. Product Development and Market Position - The company’s main product, glucosamine hydrochloride capsules, has captured over 41% market share in 9 provinces and has been successfully included in centralized procurement in 22 provincial regions[19]. - The company’s product, Torasemide injection, successfully entered the national centralized procurement for the eighth batch on March 29, 2023[20]. - The company is focusing on high-end small varieties of "marine drugs" and "major disease medications" to enhance its product positioning advantage[21]. - The company plans to continue increasing product research and development as well as pursuing external acquisitions to expand its product line[21]. - The company’s glucosamine hydrochloride capsules are included in the National Medical Insurance Directory, ensuring a stable market demand[21]. - The company has developed a competitive edge by exporting raw materials and collaborating with high-end clients, achieving quality above national standards[21]. - The company has established a strong marketing network, particularly in the Shanghai Hongqiao business district, to enhance sales capabilities[24]. - The company has 14 new products in development, with key products like paracetamol injection and dobutamine hydrochloride raw materials successfully accepted for review[25]. Financial Management and Cash Flow - Sales expenses increased by 31.40% to 71.62 million yuan, primarily due to higher marketing costs in the formulation market[26]. - The operating cash flow decreased by 38.45% to 107.39 million yuan, indicating potential liquidity challenges[26]. - The net cash flow from operating activities decreased primarily due to increased payments for raw materials, employee salaries, and taxes[27]. - The net cash flow from investing activities increased due to higher prepayments for the solid preparation project in health products[27]. - The net cash flow from financing activities decreased as the new bank loan amount was reduced year-on-year[27]. - Cash and cash equivalents decreased by 39.76% to ¥177,180,581.95, mainly due to repayment of bank loans[28]. - Accounts receivable financing increased by 104.93% to ¥33,629,524.49, primarily due to an increase in customer settlements via notes[28]. - Other receivables increased by 299.23% to ¥11,467,653.05, mainly due to unreceived dividends from Kang Le Pharmaceutical[28]. - Short-term borrowings decreased by 46.43% to ¥62,849,625.56, primarily due to a reduction in bank loans[29]. - The company reported a significant increase in other non-current assets by 48.95% to ¥24,478,344.14, mainly due to prepayments for health product projects[29]. Environmental Compliance and Sustainability - The company has maintained compliance with environmental standards, with no pollution incidents reported during the first half of 2024[39]. - The company emphasizes sustainable development and aims to build a green enterprise through pollution prevention measures[39]. - The company has not faced any environmental protection administrative penalties during the reporting period[39]. - The average concentration of chemical oxygen demand (COD) emissions was 45 mg/L, with a total discharge of 0.349 tons from January to June 2024[39]. - The average concentration of ammonia nitrogen emissions was 0.994 mg/L, with a total discharge of 0.0077 tons during the same period[39]. - The company has established a focus on environmental protection and sustainable development, with no exceedances of emission standards reported[46]. - The company has implemented an emergency response plan for environmental incidents, which was approved by local environmental authorities in November 2022[54]. - The company has taken measures to reduce carbon emissions, including the installation of solar rooftop photovoltaic systems and smart energy digital management[55]. Corporate Governance and Shareholder Information - The company did not propose any profit distribution plan or capital reserve transfer to share capital during this reporting period[3]. - The company reported no non-operating fund occupation by controlling shareholders or related parties[3]. - The company has elected a new supervisor, Chen Xiaofang, to replace Su Liping, who retired due to reaching the legal retirement age[37]. - The total number of ordinary shareholders as of the end of the reporting period was 16,076[63]. - The largest shareholder, Yan Yiyi, holds 77,192,080 shares, representing 23.58% of the total shares[64]. - The second-largest shareholder, the National Social Security Fund 604 Portfolio, holds 15,250,320 shares, representing 4.66%[64]. - The company reported no significant litigation or arbitration matters during the reporting period[62]. - There were no changes in the company's share capital structure during the reporting period[63]. - The company has not disclosed any major related party transactions during the reporting period[61]. Accounting and Financial Reporting - The financial statements were approved by the board on August 19, 2024, indicating a commitment to transparency and compliance[102]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring accurate financial reporting[106]. - The reporting period for the financial statements was from January 1, 2024, to June 30, 2024[107]. - The company uses RMB as its functional currency for financial reporting, with foreign subsidiaries reporting in their local currencies[109]. - The company recognizes goodwill when the acquisition cost exceeds the fair value of identifiable net assets acquired[112]. - The company assesses whether multiple transactions should be treated as a bundled transaction based on specific criteria[113]. - The company applies equity method accounting for joint ventures, recognizing its share of assets, liabilities, and income from joint operations[117]. - The company emphasizes the importance of accurate financial reporting and compliance with accounting standards in its financial practices[121]. Employee Compensation and Benefits - The company recognizes employee compensation liabilities, including short-term salaries, bonuses, and social insurance contributions, as liabilities during the accounting period when services are provided[177]. - The company accounts for post-employment benefits under defined contribution and defined benefit plans, with liabilities recognized based on government regulations for pension and unemployment insurance contributions[178]. - Termination benefits are recognized as liabilities when the company cannot unilaterally withdraw the plan or when costs related to restructuring are confirmed, with liabilities measured if expected to be paid beyond twelve months treated as long-term[179]. Revenue Recognition and Government Grants - The company recognizes revenue when control of the goods is transferred to the customer, which occurs upon customer acceptance and possession of the goods[186]. - Revenue is confirmed based on the completion of internal shipping procedures and receipt of customer acknowledgment, with legal ownership transferred at that point[186]. - The company recognizes government grants upon actual receipt or when there is clear evidence of eligibility for expected funds[189]. - The company adopts the total amount method for accounting government subsidies, recognizing related subsidies as deferred income and amortizing them over the useful life of the related assets[190].

证券代码：603811 证券简称：诚意药业 公告编号：2024-026 浙江诚意药业股份有限公司 关于2024年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所发布的《上市公司行业信息披露指引第六号——医药制造》和《关 于做好上市公司2024年半年度披露工作的通知》要求，现将浙江诚意药业股份有限公司（以 下简称"公司"）2024年半年度主要经营数据披露如下： 一、报告期内，公司主营业务分行业、分产品经营情况： 单位：元 币种：人民币 | | | 主营业务分行业情况 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 分行业 | 营业收入 | 营业成本 | 毛利率 （%） | 营业收入 比上年增 | 营业成本 比上年增 | 毛利率比 上年增减 | | | | | | 减（%） | 减（%） | （%） | | 医药制造业 | 354,830,222.06 | 107,284,168.21 | 69.76 | 10.77 | - ...

证券代码：603811 证券简称：诚意药业 公告编号：2024-027 浙江诚意药业股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 08 月 21 日(星期三) 至 08 月 27 日(星期 二)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 office@chengyipharma.com 进行提问。公司将在说明 会上对投资者普遍关注的问题进行回答。 浙江诚意药业股份有限公司（以下简称"公司"）于 2024 年 8 月 21 日发布公司 2024 年半年度报告，为便于广大投资者更全面深入地 了解公司 2024 年上半年经营成果、财务状况，公司计划于 2024 年 08 月 28 日 下午 13:00-14:00 举行 2024 年半年度业绩说明会，就投 资者关心的问题进行交流。 一、 说明会类型 本 ...

证券代码：603811 证券简称：诚意药业 公告编号：2024-025 浙江诚意药业股份有限公司 关于公司控股股东之一致行动人 增持计划实施结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ·增持计划的基本情况：浙江诚意药业股份有限公司（以下简称"公司"） 于2024年2月23日披露了《浙江诚意药业股份有限公司关于控股股东增加一致行 动人暨控股股东之一致行动人增持公司股份及增持计划的公告》（公告编号： 2024-006），公司控股股东颜贻意先生之一致行动人温州市洞头区诚意小额贷 款股份有限公司（以下简称"诚意小贷"）于2024年2月22日起6个月内通过上 海证券交易所系统以集中竞价方式增持公司A股股份，增持金额不低于人民币 1,500万元（含），不超过人民币3,000万元（含）。 1.增持主体：本次增持主体为公司控股股东之一致行动人温州市洞头区诚 意小额贷款股份有限公司，公司控股股东颜贻意先生为诚意小贷法定代表人及 董事长，持有诚意小贷27.50%股权。 2.增持主体的持股情况：诚意小贷在本次增持前未持 ...

证券代码：603811 证券简称：诚意药业 公告编号：2024-024 浙江诚意药业股份有限公司 关于政府对子公司土地及附属资产有偿回收的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、浙江诚意药业股份有限公司（以下简称"公司"）于2024年6月28日召开第四届 董事会第九次会议，审议通过《关于子公司江苏诚意药业有限公司出售资产的议案》， 同意江苏诚意药业有限公司（以下简称"江苏诚意"）将位于淮安市清江浦区西安南路 328号所有的土地、房产、附属物装潢、附属设施、隐蔽工程、约定收购的设备（根据 房地产估价报告中有评估价格一栏对应的清单确定）、绿化等交由淮安市清江浦区政府 下属的淮安市清江浦区宁淮浦顺投资发展有限公司（以下简称"宁淮浦顺投资公司"） 有偿回收。根据资产评估结果，协商确定收购费用总额为人民币12,698.80万元。 2、本次交易不构成关联交易，也不构成《上市公司重大资产重组管理办法》规定的 重大资产重组情形。 3、本次交易经诚意药业第四届董事会第九次会议审议通过，无需提交股东大会审议。 4 ...

浙江诚意药业股份有限公司 关于《未来三年（2023-2025 年）股东分红回报规划》 为兼顾浙江诚意药业股份有限公司（以下简称"公司"）自身发展与对股东 的合理投资回报，保护投资者的合法权益，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《上市公司监管指引第 3 号——上市公司现金分红》等相 关法律、法规、规范性文件，以及《浙江诚意药业股份有限公司章程》（以下简 称"《公司章程》"）的规定，特制定《浙江诚意药业股份有限公司未来三年 （2023-2025 年）股东分红回报规划》（以下简称"本规划"）。具体如下： 一、本规划的制定原则 公司实施积极的利润分配政策，重视对投资者的合理投资回报并兼顾公司的 可持续发展，实行连续、稳定的利润分配政策。同时结合公司经营现状和业务发 展目标，保证公司利用现金分红后留存的未分配利润和自有资金，能够促使公司 未来经营的进一步稳健增长，给股东带来长期的投资回报。 二、制定本规划的考虑因素 公司在制定股东分红回报规划时着眼于公司长远和可持续发展，综合考虑公 司发展阶段、发展目标、经营模式、盈利水平、项目投资资金需求等实际情况， 建立对投资者持续、稳定、科学、合理的回报规 ...

证券代码：603811 证券简称：诚意药业 公告编号：2024-023 浙江诚意药业股份有限公司 2023 年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.2 元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2024/6/7 | － | 2024/6/11 | 2024/6/11 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 三、 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2024/6/7 | － | 2024/6/11 | 2024/6/11 | 1. 发放年度：2023 年年度 2. 分派对象： 四、 分配实施办法 1. 实施办法 本次利润分配方案经公司 2 ...

证券代码：603811 证券简称：诚意药业 公告编号：2024-022 2024 年 5 月 22 日，公司在上海证券交易所网站（www.sse.com.cn）及指定信 息媒体披露了《浙江诚意药业股份有限公司关于召开 2023 年度暨 2024 年第一季度 业绩说明会的公告》（公告编号：2024-021）。 2024 年 5 月 29 日 13:00-14:30，公司总经理赵春建先生、副总经理任秉钧先 生、营销中心总经理罗飞跃先生、董事会秘书柯泽慧女士、财务总监吕孙战先生、 独立董事陈志刚先生出席了本次业绩说明会。与投资者进行互动交流和沟通，就投 资者关注的问题进行了回复。 二、投资者提出的主要问题及公司回复情况 1.关节类药物在 2023 年的具体收入以及其占总营收的比例是多少？这种增长 速度是否符合公司之前的预期？ 答：2023 年公司关节类药物营业收入实现 4.07 亿元，同比增长 14.61%，占总 主营业务比重为 60.7%。氨糖作为公司重点产品一直维持着稳定较好的增长，为公 司业绩表现提供了重要支撑。 2.面对国内外经济环境的不确定性，诚意药业如何调整其财务策略以应对可 能的市场波动和风险？ 答： ...

证券代码：603811 证券简称：诚意药业 公告编号：2024-021 浙江诚意药业股份有限公司 关于召开 2023 年度暨 2024 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （二）会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） （三）会议召开方式：上证路演中心视频直播和网络互动 三、 参加人员 总经理：赵春建 重要内容提示： 浙江诚意药业股份有限公司（以下简称"公司"）已于 2024 年 4 月 26 日发布公司《2023 年年度报告》和《2024 年第一季度报告》， 为便于广大投资者更全面深入地了解公司 2023 年度和2024 年第一季 度经营成果、财务状况，公司计划于 2024 年 05 月 29 日（星期三） 下午 13:00-14:30 举行 2023 年度暨 2024 年第一季度业绩说明会，就 投资者关心的问题进行交流。 会议召开时间：2024 年 05 月 29 日(星期三) 下午 13:00-14:30 会议召 ...